Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02867371
• Date of registration: 11/08/2016
• Prospective Registration: No
• Primary sponsor: Broncus Medical Inc
• Public title: Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2 EAST2
• Scientific title: Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2
• Date of first enrolment: August 2016
• Target sample size: 166
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02867371
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).
• Phase: N/A

Countries of recruitment

China, Germany, Hong Kong, United States

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Age 21-75 years at screening

2. Highly suspicious pulmonary nodule(s), defined as distinct nodule with a diameter of
=8mm in its largest dimension

3. No known endobronchial tumor

4. Tumor located anywhere in parenchymal tissue >1 cm from pleura and accessible
bronchoscopically through a POE.

5. Willing to participate in all aspects of study protocol for duration of study

6. Able to understand study requirements

7. Subject or legally authorized representative signs study-related informed consent
document

Exclusion Criteria:

1. Any contraindication to bronchoscopy, for example:

1. Untreatable life-threatening arrhythmias

2. Inability to adequately oxygenate the patient during the procedure

3. Acute respiratory failure with hypercapnia (unless the patient is intubated and
ventilated)

4. Recent myocardial infarction

5. Previously diagnosed high-grade tracheal obstruction

6. Uncorrectable coagulopathy

2. Known coagulopathy

3. Platelet dysfunction or platelet count < 100 x 103 cells/mm3

4. History of major bleeding with bronchoscopy

5. Suspected pulmonary hypertension: additional testing required, such as echocardiogram

6. Moderate-to-severe pulmonary fibrosis

7. Severe emphysema or COPD: additional testing and PI consent is required

8. Bullae >5 cm located in vicinity of target nodule or tunnel

9. Any other severe or life-threatening comorbidity that could increase the risk of
bronchoscopic biopsy or ATV tunneling, for example:

1. ASA class > 3

2. > stage 3 heart failure

3. severe cachexia

4. severe respiratory insufficiency or hypoxia

10. Ongoing systemic infection

11. Contraindication to general anesthesia

12. Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents
(e.g. aspirin, clopidogrel) prior to procedure

13. Participation in any other study in last 30 days

14. Prior thoracic surgery on the same side of the lung as the SPN.

15. Breastfeeding women or females of childbearing potential with a positive pregnancy
test prior to the procedure or the intent to become pregnant during the study.

16. Life expectancy of less than one year.

17. Scheduled for lung surgery within 72hrs post-scheduled diagnostic bronchoscopy

18. Prior radiation therapy treatment in the target lobe



Age minimum: 21 Years
Age maximum: 80 Years
Gender: All

Health Condition(s) or Problem(s) studied

Lung Cancer

Intervention(s)

Device: Archimedes System

Primary Outcome(s)

Proportion of biopsies yielding tissue sufficient for diagnosis [Time Frame: Up to 1 year]

Secondary Outcome(s)

Fluoroscopy time [Time Frame: Up to 1 year]

Nodule access time [Time Frame: Up to 1 year]

Procedure planning time [Time Frame: Up to 1 year]

Patient registration time [Time Frame: Up to 1 year]

Secondary ID(s)

Protocol 44

Source(s) of Monetary Support

Please refer to primary and secondary sponsors